Patents Assigned to Actimed Therapeutics Limited
  • S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
    Patent number: 11938102
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: March 26, 2024
    Assignee: ACTIMED THERAPEUTICS LIMITED
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Oxprenolol compositions for treating cancer
    Patent number: 11433036
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: September 6, 2022
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
    Patent number: 11007158
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 18, 2021
    Assignee: ACTIMED THERAPEUTICS LIMITED
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Oxprenolol compositions for treating cancer
    Patent number: 10828270
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 10, 2020
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Oxprenolol compositions for treating cancer
    Patent number: 10398658
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 3, 2019
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J.S. Coats, Stefan Anker, Jochen Springer